Cargando…

P1280: COMPARING TRANSPLANT OUTCOMES OF AML PATIENTS FOR 2017 AND 2022 ELN RISK STRATIFICATION: A REAL-WORLD STUDY FROM A SINGLE CENTER IN CHINA

Detalles Bibliográficos
Autores principales:	Zhang, Haixiao, Jiang, Erlie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430529/ http://dx.doi.org/10.1097/01.HS9.0000972008.51929.aa

Ejemplares similares

P508: THE PROGNOSTIC SIGNIFICANCE OF THE MEASURABLE RESIDUAL DISEASE STATUS WITHIN THE THREE AML ELN2022 RISK GROUPS
por: Bischof, Lara, et al.
Publicado: (2023)

P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
por: Huber, Sandra, et al.
Publicado: (2023)

AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report
por: Pogosova-Agadjanyan, Era L., et al.
Publicado: (2020)

ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
por: Buccisano, Francesco, et al.
Publicado: (2022)

Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2022)

ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2020)

Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network
por: Termini, Christina M., et al.
Publicado: (2023)

S138: VALIDATION OF THE REVISED 2022 EUROPEAN LEUKEMIANET (ELN) RISK STRATIFICATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Bill, Marius, et al.
Publicado: (2023)

P1281: REFRACTORY PATIENTS WITH FAVORABLE/INTERMEDIATE-RISK AML BENEFIT FROM AZACYTIDINE MAINTENANCE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Zheng, Xinhui, et al.
Publicado: (2023)

1280. Real-World Comparison of HIV-ASSIST with Expert Opinion in Selecting Antiretroviral Therapy for Complex Patients
por: Tang, Michael E, et al.
Publicado: (2022)

Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC
por: Huber, Sandra, et al.
Publicado: (2023)

P412: TRANSCRIPTOMIC CLASSIFICATION, RISK STRATIFICATION AND THERAPY SELECTION IN AML
por: Severens, Jeppe, et al.
Publicado: (2023)

Secondary-Type Mutations in Acute Myeloid Leukemia: Updates from ELN 2022
por: Bouligny, Ian M., et al.
Publicado: (2023)

P1280: TARGETED INHIBITION OF DHODH IS SYNERGISTIC WITH BCL2 BLOCKADE IN LYMPHOMA WITH CONCURRENT MYC AND BCL2 REARRANGEMENT
por: Mo, W., et al.
Publicado: (2022)

Adverse Impact of DNA Methylation Regulatory Gene Mutations on the Prognosis of AML Patients in the 2017 ELN Favorable Risk Group, Particularly Those Defined by NPM1 Mutation
por: Yu, James, et al.
Publicado: (2021)

P541: REAL-WORLD USE OF VENETOCLAX (VEN) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) IN A US REAL-WORLD EVIDENCE DATABASE (COTA)
por: Zeidan, Amer M., et al.
Publicado: (2023)

P434: MYELODYSPLASIA-RELATED MUTATIONS IN THE NEW ELN CLASSIFICATION: DOES CLONAL SIZE PLAY A ROLE?
por: Rausch, Christian, et al.
Publicado: (2023)

P560: IMPROVEMENT IN OVERALL AND RELAPSE FREE SURVIVAL OF AML PATIENTS OVER THE AGE OF 75 SINCE THE APPROVAL OF VENETOCLAX IN A REAL-WORLD SINGLE CENTER STUDY.
por: Moshe, Yakir, et al.
Publicado: (2023)

Experiences with a researcher-centric ELN
por: Badiola, Katrina A., et al.
Publicado: (2015)

The New ELN Recommendations for Treating CML
por: Hehlmann, Rüdiger
Publicado: (2020)

1280. In-Vitro Activity of Cefiderocol, Imipenem/Relebactam, & Ceftazidime/Avibactam in Ceftolozane/Tazobactam Resistant Strains of Multidrug Resistant Pseudomonas aeruginosa
por: Navas, Daniel, et al.
Publicado: (2020)

P499: APPLICABILITY OF 2022 CLASSIFICATIONS OF ACUTE MYELOID LEUKEMIA IN THE REAL-WORLD SETTING
por: Attardi, Enrico, et al.
Publicado: (2023)

P572: REAL-WORLD MANAGEMENT AND OUTCOMES FOR NEWLY DIAGNOSED AML PATIENTS INITIATING VENETOCLAX AND HYPOMETHYLATING AGENTS IN US COMMUNITY PRACTICE
por: Wang, Yuexi, et al.
Publicado: (2023)

A Clinical and Genetic Study of 1,280 Cases of Mental Defect
Publicado: (1938)

Corrigendum to ‘A More Fitting Approach to Mask Policy’ The American Journal of Medicine, Volume 135, Issue 11 (2022) 1280-1281
por: Levine, Marc
Publicado: (2023)

Institutional ELN/LIMS deployment: Highly customizable ELN/LIMS platform as a cornerstone of digital transformation for life sciences research institutes
por: Argento, Nicolas
Publicado: (2020)

Impact of comorbidities on clinical prognosis in 1280 patients with different types of COVID-19
por: Fang, Huilin, et al.
Publicado: (2021)

SCD and MTHFD2 inhibitors for high‐risk acute myeloid leukaemia patients, as suggested by ELN2017‐pathway association
por: Kim, Han Sun, et al.
Publicado: (2023)

P549: EFFICACY AND TOXICITY OF CPX-351 IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML): THE MULTICENTER REAL-WORLD EXPERIENCE FROM THE “ITALIAN TRIVENETO REGISTRY”.
por: Luca Morelli, Gian, et al.
Publicado: (2023)

What is VaxEln really like?: a user's view
por: Burkimsher, Paul C
Publicado: (1985)

MicroRNA-1280 Inhibits Invasion and Metastasis by Targeting ROCK1 in Bladder Cancer
por: Majid, Shahana, et al.
Publicado: (2012)

Upregulation of MiR-1280 Expression in Non-small Cell Lung Cancer Tissues
por: Xu, Li-Min, et al.
Publicado: (2015)

1280. Geospatial Spread of HIV in the Cologne-Bonn Region, Germany: From 2001 to 2016
por: Stecher, Melanie, et al.
Publicado: (2018)

P1266: THE SKIRT CALCULATOR DYNAMICALLY TRACKS IMMUNE RECONSTITUTION AND PREDICTS CLINICAL OUTCOME AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Cao, Yigeng, et al.
Publicado: (2023)

P1282: MOCRAVIMOD IMPROVES OVERALL SURVIVAL IN AML PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
por: Medinger, Michael, et al.
Publicado: (2023)

P973: REAL-WORLD STUDY ON ADOPTION OF STANDARD OF CARE (SOC) FOR FRONTLINE TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (FLTEMM) PATIENTS BETWEEN 2017 AND 2020/2021 ACROSS FRANCE, GERMANY, SPAIN, AND ITALY
por: Weisel, K., et al.
Publicado: (2022)

Ferroptosis-related gene signature predicts the clinical outcome in pediatric acute myeloid leukemia patients and refines the 2017 ELN classification system
por: Tao, Yu, et al.
Publicado: (2022)

Subnuclear physics: the first 50 years, highlights from Erice to ELN
por: Zichichi, A, et al.
Publicado: (2000)

Subnuclear physics: the first fifty years, highlights from Erice to ELN
por: Zichichi, Antonino, et al.
Publicado: (1998)

openBIS ELN-LIMS: an open-source database for academic laboratories
por: Barillari, Caterina, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_e5d53vq5j14af4s0fuj1al2ne9